Advertisement
Advertisement
AZN
AstraZeneca PLC
185.24
USDSponsored
+1.17
+0.64%
Mar 24, 14:30 UTC -4
Open
AZN Earnings Reports
Positive Surprise Ratio
AZN beat 25 of 40 last estimates.
63%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$15.20B
/$2.63
Implied change from Q4 25 (Revenue/ EPS)
-1.92%
/+24.06%
Implied change from Q1 25 (Revenue/ EPS)
+11.90%
/+5.62%
AstraZeneca PLC earnings per share and revenue
On Feb 10, 2026, AZN reported earnings of 2.12 USD per share (EPS) for Q4 25, missing the estimate of 2.15 USD, resulting in a -1.50% surprise. Revenue reached 15.50 billion, compared to an expected 15.96 billion, with a -2.87% difference. The market reacted with a +2.87% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of 2.63 USD, with revenue projected to reach 15.20 billion USD, implying an increase of 24.06% EPS, and decrease of -1.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.52
Actual
-$1.02
Surprise
+32.82%
Alvotech Ordinary Shares
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.37
Surprise
-706.10%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Mar 20, 2026 For Q4 25
Estimate
-$0.16
Actual
-$0.16
Surprise
+1.96%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
FAQ
What were AstraZeneca PLC's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, AstraZeneca PLC reported EPS of $2.12, missing estimates by -1.5%, and revenue of $15.50B, -2.87% below expectations.
How did the market react to AstraZeneca PLC's Q4 2025 earnings?
The stock price moved up 2.87%, changed from $188.01 before the earnings release to $193.40 the day after.
When is AstraZeneca PLC expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for AstraZeneca PLC's next earnings report?
Based on 7
analysts, AstraZeneca PLC is expected to report EPS of $2.63 and revenue of $15.20B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement